Incorporating ctDNA-Based MRD Testing and Study Findings Into Clinical Practice

Opinion
Video

Medical experts examine how recent data on circulating tumor DNA-based minimal residual disease testing may impact the clinical management and treatment of colorectal cancer.

  1. Please discuss the clinical implications of these recent data for the utility of ctDNA-based MRD testing in CRC treatment and management
    • Are any of these findings practice-changing?
    • Are you routinely testing patients after surgery and after adjuvant therapy on the basis of these data?
  2. What are some barriers to enrollment surrounding MRD testing in CRC for ongoing adjuvant studies (like CIRCULATE)?
    • Are patients wanting to escalate or de-escalate treatment?
    • How are patients reacting to study testing?
Recent Videos
Alessio Pigazzi, MD, PhD, FACS, FASCRS, discussed surgical and medical oncology developments in the colorectal cancer field.
A panel of 3 experts on CML
A panel of 3 experts on CML
The Onc Brothers feature one guest in this series.
The Onc Brothers feature one guest in this series.
The Onc Brothers feature one guest in this series.
Related Content
Improved overall survival was also noted when atezolizumab plus bevacizumab and FOLFOXIRI were used to treat patients with pMMR tumors.

Atezolizumab Combo Improves Survival in Metastatic CRC

Ariana Pelosci
August 22nd 2024
Article

Improved overall survival was also noted when atezolizumab plus bevacizumab and FOLFOXIRI were used to treat patients with pMMR tumors.

Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

Optimizing Metastatic CRC Outcomes Following Fruquintinib Approval

Jagoda Misniakiewicz, PharmD
June 10th 2024
Podcast

Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

Managing high-grade squamous intraepithelial lesions may reduce the risk of anal cancer based on data from the phase 3 ANCHOR trial.

New HIV Guidelines Recommend Screening to Mitigate Anal Cancer Risk

Roman Fabbricatore
August 12th 2024
Article

Managing high-grade squamous intraepithelial lesions may reduce the risk of anal cancer based on data from the phase 3 ANCHOR trial.

Surgical oncologists from Cleveland Clinic discuss the National Accreditation Program for Rectal Cancer and its aim to improve patient outcomes.

Ensuring Quality Rectal Cancer Surgery at NAPRC-Accredited Institutions

Steven Wexner, MD, PhD;Arielle Kanters, MD
May 27th 2024
Podcast

Surgical oncologists from Cleveland Clinic discuss the National Accreditation Program for Rectal Cancer and its aim to improve patient outcomes.

The recommendation was made following mid-stage, end-of-phase 2 data for the botensilimab/balstilimab combination, which yielded lower responses in patients.

FDA Discourages Accelerated Approval of Botensilimab/Balstilimab Combo in R/R MSS CRC

Roman Fabbricatore
July 19th 2024
Article

The recommendation was made following mid-stage, end-of-phase 2 data for the botensilimab/balstilimab combination, which yielded lower responses in patients.

Expert Commentary on the Product Profile of Fruquintinib in Metastatic CRC

Expert Commentary on the Product Profile of Fruquintinib in Metastatic CRC

Jagoda Misniakiewicz, PharmD
July 11th 2024
Article

Jagoda Misniakiewicz, PharmD, discussed implementing fruquintinib into clinical practice and how it's mechanism of action compares with others in the space.